代漢仁，教授

研究方向：細胞免疫治療

電子郵箱：daihanren@ahmu.edu.cn

教育經(jīng)歷：

(1) 2017/09–2020/06，南京大學，藥學，博士

(2) 2012/09–2015/06，解放軍醫(yī)學院,生物化學與分子生物學,碩士

(3) 2005/09–2009/07，蚌埠醫(yī)學院,生物科學,學士

工作經(jīng)歷：

(1) 2024/01至今，安徽醫(yī)科大學，藥學院，教授

(2) 2020/10-2023/10，安徽醫(yī)科大學第一附屬醫(yī)院，博士后

(3) 2009/09-2017/06，中國人民解放軍總醫(yī)院，基礎醫(yī)學研究所

科研項目：

（1）國家自然科學基金，面上項目，82470656，靶向活化肝星狀細胞的FAP-CAR-T細胞治療肝纖維化，2025/01-2028/12，46萬元，在研，主持

（2）安徽省教育廳，CART細胞治療器官纖維化，安徽省高校科研計劃優(yōu)秀青年項目，2024AH030023，2025/01-2027/12，50萬元，主持

（3）國家自然科學基金，面上項目，82270641，CAR修飾巨噬細胞靶向殺傷肝星狀細胞治療肝纖維化，2023/01-2026/12，52萬元，在研，主持

（4）國家自然科學基金，青年基金項目，81602711，雙靶向CD19/CD22嵌合抗原受體治療急性B淋巴細胞白血病的應用基礎研究，2017/01-2019/12，17萬元，結題，主持

（5）中國博士后科學基金第69批面上資助二等，2021M690186, 8萬，結題，主持

發(fā)表論文情況：

1.Dai H?, Zhu C?, Huai Q, Xu W, Zhu J, Zhang X, Zhang X, Sun B, Xu H, Zheng M, Li X*, Wang H*. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. Journal of Hepatology. 2024 Feb 8:S0168-8278(24)00113-2.  (IF=26.8，ESI高被引論文)

2.Li X, Huai Q, Zhu C, Zhang X, Xu W,Dai H*, Wang H*. GDF15 ameliorates liver fibrosis by metabolic reprogramming of macrophages to acquire anti-inflammatory properties.Cellular and Molecular Gastroenterology and Hepatology.2023;16(5):711-734.(IF=7.2)

3.Li X?,Dai H?, Wang Y?, Wu Z?, Wang H, Qian W, Liang A, Han W. Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China.Lancet Haematol. 2022 Dec;9(12):e942-e954. (IF=24.7)

4.Wang Y?, Tong C?,Dai H?, Wu Z?, Han X?, Guo Y, Chen D, Wei J, Ti D, Liu Z, Mei Q, Li X, Dong L, Nie J, Zhang Y, Han W. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.Nat Commun.2021 Jan 18;12(1):409. (IF=17.694)

5.Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, Han X, Wang H, Wang Y, Shen P. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020 Nov 25;9(1):1846926.(IF=8.11)

6.Dai H?, Wu Z?, Jia H?, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, Zhang Y, Chen M, Yang Q, Wang Y, Han W. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020 Apr 3;13(1):30. (IF=23.168，ESI高被引論文)

7.Dai H, Zhou Y, Tong C, Guo Y, Shi F, Wang Y*, and Shen P*.Restoration of CD3+CD56+ cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells. Cytotherapy. 2018 Sep;20(9):1155-1163(IF=6.196)

8.Zhang Y?, Zhang W?,Dai H?, Wang Y, Shi F, Wang C, Guo Y, Liu Y, Chen M, Feng K, Zhang Y, Liu C, Yang Q, Li S, Han W*. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Sci China Life Sci. 2016 Apr;59(4):379-85.(IF=10.372)

9.Feng K?, Guo Y?,Dai H?, Wang Y, Li X, Jia H, Han W*. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.Sci China Life Sci. 2016 May;59(5):468-79.(IF=10.372)

10.Dai H?, Zhang W?, Li X?, Han Q?, Guo Y, Zhang Y, Wang Y, Wang C, Shi F, Zhang Y, Chen M, Feng K, Wang Q, Zhu H, Fu X, Li S*, Han W*.  Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015; 4(11): e1027469.(IF=8.11)

11.Wang Y?, Bo J?,Dai HR?, Lu XC, Lv HY, Yang B, Wang T, Han WD*. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.Exp Hematol. 2013 Mar;41(3):241-52.e3.(IF=3.249)

12.Wang Y?,Dai H?, Li H?, Lv H, Wang T, Fu X*, Han W*. Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin Dev Immunol. 2011;2011:621414. (IF=4.493)

13.Dai H?, Wang Y?, Lu X, Han W*. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst. 2016 Jan 27;108(7).(IF=12.583)